About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5570964
Allelic
Composition
Tg(Shank3-EGFP)1Hzo/0
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Shank3-EGFP)1Hzo mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
• duration of immobility is less than in wild-type mice in a tail-suspension test
• mice do not habituate during the open field test
• elevation in acoustic startle response
• valproate treatment reverses the abnormal startle response
• increase in locomotor activity and speed in the open field test
• females exhibit increased home-cage activity
• an acute injection of amphetamine aggravates the hyperactivity to a greater degree than in wild-type mice
• lithium treatment does not mitigate any of the manic-like behaviors of mice
• valproate treatment reverses the hyperactivity
• however, mice do not exhibit repetitive behavior
• increase in locomotor activity and speed in the open field test
• abnormal circadian rhythms, with some mice showing complete loss of rhythm when placed into constant darkness
• mice show increased period length and activity count, but normal alpha
• decrease in social interaction, with mice spending less time in close interaction with novel social partners
• mice do not show a preference for novel mice to novel objects
• mice make fewer calls during an ultrasonic vocalization test at P13
• spontaneous seizures
• EEG shows hyperexcitability discharges accompanied by electrographic seizures
• seizures result from a synaptic excitatory/inhibitory inbalance that is shifted towards excitation
• valproate treatment decreases the frequency of epileptiform spikes

growth/size/body
• at 9 and 15 weeks of age

nervous system
• spontaneous seizures
• EEG shows hyperexcitability discharges accompanied by electrographic seizures
• seizures result from a synaptic excitatory/inhibitory inbalance that is shifted towards excitation
• valproate treatment decreases the frequency of epileptiform spikes
• hippocampal pyramidal neurons exhibit reduced number of inhibitory synapses
• density of dendritic spines is increased
• hippocampal pyramidal neurons exhibit reduced number of inhibitory synapses
• amplitude of spontaneous excitatory postsynaptic current (EPSC is) increased in CA1 hippocampal pyramidal neurons
• however, AMPA receptor-mediated miniature EPSC is normal and basal synaptic transmission at Schaffer collateral-CA1 synapses is normal
• CA1 hippocampal pyramidal neurons show a reduction in GABA(A) receptor-mediated miniature inhibitory postsynaptic current (mIPSC) frequency, but not in amplitude or decay time
• reduction in prepulse inhibition
• valproate treatment reverses the impaired prepulse inhibition

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
chromosome 22q13 duplication syndrome DOID:0060437 OMIM:615538
J:201867


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/12/2024
MGI 6.23
The Jackson Laboratory